Piper Sandler analyst Christopher Raymond expects shares of BioMarin (BMRN) "will be up meaningfully on the open" after competitor Ascendis Pharma (ASND) reported results of the ACcomplisH trial, a Phase 2 randomized, placebo controlled trial of TransCon CNP in children age 2-10. "What we got was anything but competitive" to BioMarin’s Voxzogo, Raymond tells investors in a research note. The analyst believes Voxzogo’s growth story is intact and he keeps an Overweight rating on BioMarin with a $128 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMRN:
